GlassScriptPhysician profile
Nita Chatterjee
NPI 1164469854
$21,883.01
in general payments reported to CMS, 2019-2025
57 companies · $3,578 in 2025
The $3,578 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,130 · 2020: $2,093 · 2021: $3,487 · 2022: $2,752 · 2023: $3,097 · 2024: $3,746 · 2025: $3,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $20.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,400.72 |
| Education | $20.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,183.74 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,966.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,828.72 | 2019-2025 | Ubrelvy, Qulipta, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,626.53 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $1,618.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,113.40 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $1,003.54 | 2019-2025 | Evenity, Repatha, Prolia |
| Teva Pharmaceuticals USA, INC. | $868.35 | 2020-2023 | Austedo Xr, Austedo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $845.48 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $754.30 | 2021-2025 | |
| Pfizer INC. | $740.33 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $570.71 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $550.84 | 2024-2025 | Voquezna |
| Allergan, INC. | $435.10 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $428.05 | 2024-2025 | Uptravi, Opsumit |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nita Chatterjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.